Slone Partners Places Chief Medical Officer at Signal Genetics
(PRWEB) November 04, 2015 -- National recruitment firm Slone Partners is pleased to announce the placement of Dr. Richard Bender as Chief Medical Officer at Signal Genetics, Inc., a commercial stage, molecular genetics diagnostic company. Dr. Bender will report to Samuel D. Riccitelli, the Company's President and Chief Executive Officer.
The Carlsbad, California company has grown its new hospital business significantly in 2015, selling a record volume of MyPRS® tests to that sub segment during the first half of the year, with Q2 showing a 70% increase over the previous year.
Samuel D. Riccitelli commented, "Dr. Bender has significant experience in both laboratory diagnostics and drug development, which will further enhance our senior management team as we work to expand our test menu and the services that we provide. With our continued growth, it is critically important that we attract leaders who are experts in our space, and who share our passion for improving the treatment of patients. Slone Partners’ knowledge of this industry has been an important success factor in attracting high quality individuals to our organization.”
Adam Slone, Chief Executive Officer of Slone Partners commented, “It was important to us that we approached our partnership strategically from the beginning, so we could ensure long term success. Signal Genetics is doing great work in improving patient care, and we are committed to a strong partnership as they continue to grow.”
About Dr. Richard Bender
Dr. Bender received his MD degree from the UCLA School of Medicine followed by specialty training in Internal Medicine at UCLA-Harbor General Hospital and in Medical Oncology/ Hematology at the National Cancer Institute. He spent 25 years in clinical practice the majority spent serving as the Medical Director for Oncology / Hematology for Kaiser Permanente in San Diego. In 2002 he transitioned to the diagnostic industry where he has been the Medical Director for Hematology / Oncology for Quest Diagnostics, Inc. and the Chief Medical Officer for Agendia, a molecular diagnostics company. He has also served on the executive board of the San Diego Hospice and American Cancer Society. He continues to teach at the UCLA School of Medicine, as well as to serve as an expert reviewer in oncology for the Medical Board of California and was recently selected to be a consultant for the Medical Devices Advisory Committee of the FDA. Dr. Bender is the author of over 75 peer-reviewed scientific articles and numerous book chapters and has been invited to speak all over the world as an expert in oncology diagnostics.
About Signal Genetics
Signal Genetics™ is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer.
The company was founded in April 2010 after becoming the exclusive licensee to the world-renowned research on multiple myeloma (MM) performed at the University of Arkansas for Medical Sciences (UAMS). Signal Genetics™’ flagship product - MyPRS® (Myeloma Prognostic Risk Signature) is based upon more than two decades of clinical research on more than 10,000 MM patients who received their care at UAMS.
Signal Genetics™ offer the MyPRS® test out of its state-of-the-art, CLIA and CAP certified reference laboratory located in Little Rock, AR. The company is dedicated to making its extensively validated diagnostic services available to all patients who need them.
About Slone Partners
Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for the diagnostics, life science tools, healthcare information technology, and laboratory testing industries. Slone Partners has offices in Boston, New York, Washington, D.C., and San Francisco.
For more information on Slone Partners placements, please view our Completed Searches.
Tara Kochis-Stach, Slone Partners, http://www.slonepartners.com, +1 (877) 416-0681, [email protected]
Share this article